Oncolytic reovirus in combination with chemotherapy in metastatic or recurrent non-small cell lung cancer patients with KRAS-activated tumors

Cancer

Volumn 122, Issue 6, 2016, Pages 875-883

  Villalona Calero, Miguel A ^a   Lam, Elaine ^a   Otterson, Gregory A ^a   Zhao, Weiqiang ^a   Timmons, Matthew ^a   Subramaniam, Deepa ^b   Hade, Erinn M ^a   Gill, George M ^c   Coffey, Matthew ^c   Selvaggi, Giovanni ^c   Bertino, Erin ^a   Chao, Bo ^a   Knopp, Michael V ^d  

^a OHIO STATE UNIVERSITY   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c ONCOLYTICS BIOTECH INC   (Canada)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

BRAF; epidermal growth factor receptor (EGFR); KRAS; lung cancer; oncolytic virus

Indexed keywords

CARBOPLATIN; PACLITAXEL; PELAREOREP; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; ASTHENIA; CANCER RECURRENCE; CANCER STAGING; CLINICAL ARTICLE; CONFUSION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; ETHNICITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FLUORESCENCE IN SITU HYBRIDIZATION; HEADACHE; HUMAN; HUMAN TISSUE; HYPERTRANSAMINASEMIA; HYPOTENSION; LUNG METASTASIS; LYMPHOCYTOPENIA; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NON SMALL CELL LUNG CANCER; ONCOGENE K RAS; ONCOLYTIC VIROTHERAPY; OVERALL SURVIVAL; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL TIME; THROMBOCYTOPENIA; VOMITING; CANCER GRADING; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE FREE SURVIVAL; GENETICS; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAMMALIAN ORTHOREOVIRUS 3; MIDDLE AGED; PATHOLOGY; PROCEDURES; TUMOR RECURRENCE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MAMMALIAN ORTHOREOVIRUS 3; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; ONCOLYTIC VIROTHERAPY; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84960418699     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29856     Document Type: Article

References (36)

1. Chakrabarty R, Tran H, Selvaggi G, Hagerman A, Thompson B, Coffey M,. The oncolytic virus, pelareorep, as a novel anticancer agent: a review. Invest New Drugs. 2015; 33: 761-764.
2. Danthi P, Holm GH, Stehle T, Dermody TS,. Reovirus receptors, cell entry, and proapoptotic signaling. Adv Exp Med Biol. 2013; 790: 42-71.
3. Strong JE, Tang D, Lee PW,. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology. 1993; 197: 405-411.
4. Strong JE, Lee PW,. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J Virol. 1996; 70: 612-616.
5. Hershey JW,. Translational control in mammalian cells. Annu Rev Biochem. 1991; 60: 717-755.
6. Strong JE, Coffey MC, Tang D, Sabinin P, Lee PW,. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J. 1998; 17: 3351-3362.
7. Roulstone V, Pedersen M, Kyula J, et al., BRAF- and MEK-targeted small molecule inhibitors exert enhanced antimelanoma effects in combination with oncolytic reovirus through ER stress. Mol Ther. 2015; 23: 931-942.
8. Maitra R, Seetharam R, Tesfa L, et al., Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan. Oncotarget. 2014; 5: 2807-2819.
9. Sei S, Mussio JK, Yang Q, et al., Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents against non-small cell lung cancer (NSCLC). Mol Cancer. 2009; 8: 47.
10. Vidal L, Pandha HS, Yap TA, et al., A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res. 2008; 14: 7127-7137.
11. Lolkema MP, Arkenau HT, Harrington K, et al., A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res. 2011; 17: 581-588.
12. Comins C, Spicer J, Protheroe A, et al., REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res. 2010; 16: 5564-5572.
13. Karapanagiotou EM, Roulstone V, Twigger K, et al., Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res. 2012; 18: 2080-2089.
14. Fleming TR,. One-sample multiple testing procedure for phase II clinical trials. Biometrics. 1982; 38: 143-151.
15. A'Hern RP,. Sample size tables for exact single stage phase II designs. Stat Med. 2001; 20: 859-866.
16. Eisenhauer E, Therasse P, Bogaerts J, et al., New response criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45: 228-247.
17. 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006; 47: 1059-1066.
18. Brown LD, Cai T, DasGupta A,. Interval estimation for a binomial proportion. Stat Sci. 2001; 16: 101-117.
19. Kaplan EL, Meier P,. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
20. Steuer CE, Khuri FR, Ramalingam SS,. The next generation of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of lung cancer. Cancer. 2015; 121: E1-E6.
21. Gainor JF, Sherman CA, Willoughby K, et al., Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib. J Thorac Oncol. 2015; 10: 232-236.
22. Metro G, Chiari R, Bennati C, et al., Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status. Clin Lung Cancer. 2014; 15: 86-92.
23. Martin P, Leighl N, Tsao M, Shepherd L,. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol. 2013; 8: 530-542.
24. Mascaux C, Iannino N, Martin B, et al., The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer. 2005; 92: 131-139.
25. Pirker R, Pereira JR, Szczesna A, et al., Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet. 2009; 373: 1525-1531.
26. O'Byrne KJ, Gatzemeier U, Bondarenko I, et al., Molecular biomarkers in non-small-cell lung cancer: a retrospective analysis of data from the phase 3 FLEX study. Lancet Oncol. 2011; 12: 795-805.
27. White CL, Twigger KR, Vidal L, et al., Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther. 2008; 15: 911-920.
28. Roulstone V, Khan K, Pandha HS, et al., Phase I trial of cyclophosphamide as an immune modulator for optimizing oncolytic reovirus delivery to solid tumors. Clin Cancer Res. 2015; 21: 1305-1312.
29. Adair RA, Roulstone V, Scott KJ, et al., Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med. 2012; 4: 138ra77.
30. Galanis E, Markovic SN, Suman VJ, et al., Phase II trial of intravenous administration of Reolysin(®) (reovirus serotype-3-Dearing strain) in patients with metastatic melanoma. Mol Ther. 2012; 20: 1998-2003.
31. Gollamudi R, Ghalib MH, Desai KK, et al., Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest New Drugs. 2010; 28: 641-649.
32. Mahalingam D, Patel S, Nuovo G, et al., The combination of intravenous Reolysin and gemcitabine induces reovirus replication and endoplasmic reticular stress in a patient with KRAS-activated pancreatic cancer. BMC Cancer. 2015; 15: 513.
33. Nuovo GJ, Garofalo M, Valeri N, et al., Reovirus-associated reduction of microRNA-let-7d is related to the increased apoptotic death of cancer cells in clinical samples. Mod Pathol. 2012; 25: 1333-1344.
34. Sborov D, Nuovo G, Stiff A, et al., A phase I trial of single agent Reolysin in patients with relapsed multiple myeloma. Clin Cancer Res. 2014; 20: 5946-5955.
35. Liu J, Spurrel J, Shi ZQ, Chen WQ, Morris DG,. Oncolytic viral therapy with immune modulation is an effective novel treatment strategy for non-small cell lung cancer [abstract]. Cancer Res. 2015; 75: 5355.
36. Rajani K, Parrish C, Kottke T, et al., Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol Ther. In press.